Laekna, Inc. (HKG:2105)

Market Cap	2.42B -60.3%
Revenue (ttm)	296.69M
Net Income	-118.02M
EPS	-0.29
Shares Out	426.15M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,601,000
Open	6.20
Previous Close	6.20
Day's Range	5.63 - 6.20
52-Week Range	5.37 - 19.36
Beta	-1.19
Analysts	Strong Buy
Price Target	23.36 (+310.91%)
Est. Earnings	Nov 25, 2026

About Laekna

Laekna, Inc., an investing holding company, engages in the discovering, development, and commercialization of therapies for patients with cancer, metabolic diseases, and liver fibrosis worldwide. The company offers LAE002, an adenosine triphosphate competitive AKT inhibitor for the treatment of ovarian cancer, prostate cancer, and breast cancer; LAE001, an androgen synthesis inhibitor that inhibits CYP17A1 and CYP11B2 to treat prostate cancer; LAE005, a ligand-blocking humanized anti-PD-L1 IgG4 antibody for the treatment of triple-negative brea...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2016
• Employees: 83
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 2105

Financial Performance

Financial numbers in CNY

Analyst Summary

According to 3 analysts, the average rating for 2105 stock is "Strong Buy." The 12-month stock price target is $23.36, which is an increase of 310.91% from the latest price.

Price Target

$23.36

(310.91% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 22, 2026

Data Sources Report a data error